

### PERSONAL INFORMATION **Sabine Straus**

#### WORK EXPERIENCE

---

July 2018- Present **PRAC chair**  
MEB (Netherlands)  
chairing the PRAC

July 2012- Present **staff member**  
MEB (Netherlands)  
PRAC member

December 2005-June 2012 **head of PhV**  
MEB (Netherlands)

2010- Present **associate professor**  
Erasmus MC (Netherlands)

2001- 2005 **senior assessor pharmacovigilance**  
MEB (Netherlands)

#### EDUCATION AND TRAINING

---

September 1978- 1985 **MD**  
university Utrecht (Netherlands)

2002- 2003 **MSc in Epidemiology**  
erasmus university (Netherlands)

2001- 2005 **PhD**  
erasmus university (Netherlands)

#### ADDITIONAL INFORMATION

---

**Expertise** signal detection /signal management  
pharmaco epidemiology  
(additional) risk minimisation, pregnancy prevention programs and assessment of effectiveness  
risk communication

**Publications** Priya Bahri, Daniel R. Morales, Adrien Inoubli, Jean-Michel Dogné , Sabine M. J. M. Straus  
Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis  
of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder  
Safety Engagement Tool (ASSET).

Drug Safety; November 2020

Aniello Santoro, Irina Caplanusi, Fergus Sweeney, Benedicte Cappelli, Lorraine Nolan, Sabine Straus, Peter Arlett

Navigating stormy waters: 10years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use

Pharmacoepidemiol Drug Saf. 2020;29:13431352.

Joanne Potts, Georgy Genov, Andrej Segec, June Raine, Sabine Straus, Peter Arlett

Improving the Safety of Medicines in the European Union: From Signals to Action

Clin Pharmacol Ther. 2020 Mar; 107(3): 521529.

Peter Arlett, Sabine Straus, Guido Rasi

Pharmacovigilance 2030: Invited Commentary for the January 2020 Futures Edition of Clinical Pharmacology and Therapeutics

Clin Pharmacol Ther. 2020 Jan; 107(1): 8991. Published online 2019 Nov 22.

Christina E. Hoeve, Reynold D. C. Francisca, Inge Zomerdijk, Miriam C. J. M. Sturkenboom, Sabine M. J. M. Straus

Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union

Drug Saf. 2020; 43(1): 4555.

Kartini Gadroen, Jeanet M Kemmeren, Patricia CJ Bruijning-Verhagen, Sabine MJM Straus, Daniel Weibel, Hester E de Melker, Miriam CJM Sturkenboom

Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012

Euro Surveill. 2017 Jun 22; 22(25): 30556. doi: 10.2807/1560-7917.ES.2017.22.25.30556

Hoeve CE, van Haren A, Sturkenboom MCJM, Straus SMJM.

Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study

Vaccine. 2018 Dec 18;36(52):7956-7964. doi: 10.1016/j.vaccine.2018.11.003. Epub 2018 Nov 8.

Francisca RDC, Zomerdijk IM, Sturkenboom MCJM, Straus SMJM.

Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.

Expert Opin Drug Saf. 2018 Oct;17(10):975-982.

Vatzaki E, Straus S, Dogne JM, Garcia Burgos J, Girard T, Martelletti P.

Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation

J Headache Pain. 2018 Aug 14;19(1):68. doi: 10.1186/s10194-018-0898-3.

Kälviäinen R, Straus S, Dogne JM, Bakchine S, Haas M

Reducing valproate use in women with epilepsy.

Lancet Neurol. 2018 Jul;17(7):580-581. doi: 10.1016/S1474-4422(18)30172-8

Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, Alteri E.

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

Drug Saf. 2018 Feb;41(2):191-202

Pacurariu AC, Coloma PM, Gross-Martirosyan L, Sturkenboom MC, Straus SM.

Decision making in drug safety-a literature review of criteria used to prioritize newly detected safety issues.

Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):327-334

Gadroen K, Kemmeren JM, Bruijning-Verhagen PC, Straus SM, Weibel D, de Melker HE, Sturkenboom MC.

Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012.

Euro Surveill. 2017 Jun 22;22(25).

Gadroen K, Straus SM, Pacurariu A, Weibel D, Kurz X, Sturkenboom MC.  
Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance.  
Vaccine. 2016 Sep 22;34(41):4892-7

de Bie S, Kaguclidou F, Verhamme KM, De Ridder M, Picelli G, Straus SM, Giaquinto C, Stricker BH, Bielicki J, Sharland M, Sturkenboom MC; ARPEC study Using Prescription Patterns in Primary Care to Derive New Quality Indicators for Childhood Community Antibiotic Prescribing.  
Pediatr Infect Dis J. 2016 Dec;35(12):1317-1323

Vermeer NS, Ebbers HC, Straus SM, Leufkens HG, Egberts TC, De Bruin ML.  
The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.  
Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):297-306.

Pacurariu AC, Straus SM, Trifirò G, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Arlett P, van der Lei J, Sturkenboom MC, Coloma PM.  
Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.  
Drug Saf. 2015 Dec;38(12):1201-10.

Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Hidalgo-Simon A, Egberts AC, Leufkens HG, De Bruin ML.  
Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.  
Clin Pharmacol Ther. 2015 Nov;98(5):542-50

Segec A, Keller-Stanislawski B, Vermeer NS, Macchiarulo C, Straus SM, Hidalgo-Simon A, De Bruin ML.  
Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy.  
Clin Pharmacol Ther. 2015 Nov;98(5):502-5.

de Bie S, Ferrajolo C, Straus SM, Verhamme KM, Bonhoeffer J, Wong IC, Sturkenboom MC; GRiP network.  
Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.  
PLoS One. 2015 Jun 19;10(6):

de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifirò G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC; EU-ADR consortium.  
The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.  
Br J Clin Pharmacol. 2015 Aug;80(2):304-14

Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, Sturkenboom M, Trifirò G.  
Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection.  
Int J Clin Pharm. 2015 Feb;37(1):94-104.

de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifirò G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC; on behalf of the EU-ADR consortium.  
The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.  
Br J Clin Pharmacol. 2015 Feb 16. [Epub ahead of print]

Niels S Vermeer, Irina Spierings, Aukje K Mantel-Teeuwisse, Sabine MJM Straus, Thijs J Giezen, Hubert GM Leufkens, Toine CG Egberts, and Marie L De Bruin

Traceability of biologicals: present challenges in pharmacovigilance

Expert Opin. Drug Saf 2014; 14(1)

Vermeer NS, Duijnhoven RG, Straus SM, Mantel-Teeuwisse AK, Arlett PR, Egberts AC, Leufkens HG, De Bruin ML.

Risk Management Plans as a Tool for Proactive Pharmacovigilance: A Cohort Study of Newly Approved Drugs in Europe.

Clin Pharmacol Ther 2014 e publication Sep 15.

Duijnhoven RG, Straus SM, Souverein PC, de Boer A, Bosch JL, Hoes AW, De Bruin ML.

Long-term use of 5-reductase inhibitors and the risk of male breast cancer.

Cancer Causes Control 2014 Nov;25(11):1577-82.

van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM.

Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide.

Am J Med. 2014 Aug;127(8):763-71.

van Blijderveen JC, Straus SM, de Ridder MA, Stricker BH, Sturkenboom MC, Verhamme KM.

Adherence to renal function monitoring guidelines in patients starting antihypertensive therapy with diuretics and RAAS inhibitors: a retrospective cohort study.

Drug Saf. 2014;37(5):369-77.

van Blijderveen JC, Straus SM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM.

A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands.

Int Urol Nephrol. 2014;46(3):583-92.

Peter G. M. Mol, Arna H. Arnardottir, Domenico Motola, Patrick J. Vrijlandt, Ruben G. Duijnhoven, Flora M. Haaijer-Ruskamp, Pieter A. de Graeff, Petra Denig, Sabine M. J. M. Straus

Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study.

Drug Saf. 2013 ;36(11):1105-15

Inge M. Zomerdijk, Gianluca Trifirò, Fakhredin A. Sayed-Tabatabaei, Miriam C. J. M. Sturkenboom and Sabine M. J. M. Straus

Measuring the effect of risk minimization measures can existing healthcare databases be used?

Pharmacoepidemiol Drug Saf. 2013;22(10):1046-53.

Niels S. Vermeer, Sabine M. J. M. Straus , Aukje K. Mantel-Teeuwisse,

Francois Domergue, Toine C. G. Egberts ,Hubert G. M. Leufkens,

Marie L. De Bruin

Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases

Drug Safety published online June 2013

Van Blijderveen JC, Verhamme KM, Zietse R, Visser LE, Romio SA, Buhre PN, Sturkenboom MC, Hofman A, Straus SM, Stricker BH

Overanticoagulation is associated with renal function decline.

J Nephrol. 2013 Jul 12;26(4):691-8

Duijnhoven RG, Straus SM, Raine JM, de Boer A, Hoes AW, De Bruin ML.

patients studied prior to approval of new medicines: a database study

Number of

PLoS Med.

2013 Mar;10(3):e1001407

Reber KC, Piening S, Wieringa JE, Straus SM, Raine JM, de Graeff PA, Haaijer-Ruskamp FM, Mol PG

When direct health care

professional communications have an impact on inappropriate and unsafe use of medicines

Clin Pharmacol Ther. 2013 Apr;93(4):360-5.

Crijns I, Mantel-Teeuwisse A, Bloemberg R, Pinas E, Straus S, de Jong-van den Berg L. Healthcare

professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. *Expert Opin Drug Saf.* 2013 Jan;12(1):29-38

Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. *Drug Saf.* 2012;35(11):1061-72.

Willemen MJ, Mantel-Teeuwisse AK, Buggy Y, Layton D, Straus SM, Leufkens HG, Egberts TC. Reasons for and Time to Discontinuation of Rimonabant Therapy: A Modified Prescription-Event Monitoring Study. *Drug Saf.* 2012 Oct 15.

Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, Straus SM, Leufkens HG, van Solinge WW, Egberts TC. Rituximab-induced thrombocytopenia: a cohort study. *Eur J Haematol.* 2012; 89(3):256-66.

de Bie S, Verhamme KM, Straus SM, Stricker BH, Sturkenboom MC. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection. *Drug Saf.* 2012;35(4):335-46.

Rijke R, Loes E. Visser, Myrthe P.P. van Herk-Sukel, Petronella H. Geelhoed-Duijvestijn, Sandra de Bie, Sabine M.J.M. Straus, Peter G.M. Mol, Silvana A. Romio, Ron M.C. Herings and Bruno H.Ch. Stricker  
Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals  
Analysis of Trends in Dispensing Patterns in the Netherlands from 1998 to 2008  
*Drug Safety* 2012;35(6) 471-480

Zomerdijk IM, Sayed-Tabatabaei FA, Trifirò G, Blackburn SC, Sturkenboom MC, Straus SM. Risk Minimization Activities of Centrally Authorized Products in the EU: A Descriptive Study. *Drug Safety* 2012; 35 (4): 299-314

Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG. Impact of safety-related regulatory action on clinical practice: a systematic review. *Drug Saf.* 2012;35(5):373-85.

Piening S, Reber KC, Wieringa JE, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, Mol PG. Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. *Clin Pharmacol Ther.* 2012;91(5):838-45.

Crijns HJ, van Rein N, Gispén-de Wied CC, Straus SM, de Jong-van den Berg LT. Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study. *Pharmacoepidemiol Drug Saf.* 2012

Crijns, Ineke; Straus, Sabine; Luteijn, Michiel; Gispén-de Wied, Christine; Raine, June; de Jong-van den Berg, Lolkje  
Implementation of the Harmonized EU Isotretinoin Pregnancy Prevention Programme: A Questionnaire Survey among European Regulatory Agencies  
*Drug Safety* 2012;35(1):27-32

Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. *Diabetes Care.* 2012 Jan;35(1):119-24

Arna H. Arnardottir, Flora M. Haaijer-Ruskamp, Sabine M.J. Straus, Pieter A. de Graeff, Peter G.M. Mol  
Effect of Safety Issues with HIV Drugs on the Approval Process of Other Drugs in the Same Class: An Analysis of European Public Assessment Reports.  
*Drug Safety* 2011;34(11):1101-1114

Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH.  
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.  
Diabetologia. 2012 Jan;55(1):51-62. Epub 2011  
14Crijns HJ, Jentink J, Garne E, Gispen-de Wied CC, Straus SM, de Jong-van den Berg LT; for the EUROCAT Working Group.  
The Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist-exposed Pregnancies Is Similar to the General Population.  
J Rheumatol. 2011;38(9):1871-1874  
Härmark L, van Puijenbroek E, Straus S, van Grootheest K.  
Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information.  
Drug Saf. 2011;34(3):221-31  
Teichert M, Visser LE, Uitterlinden AG, Hofman A, Buhre PJ, Straus S, De Smet PA, Stricker BH.  
Selective serotonin reuptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment.  
Br J Clin Pharmacol. 2011 May 4  
Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, Eichler HG, de Graeff PA, Mol PG.  
Additional safety risk to exceptionally approved drugs in Europe?  
Br J Clin Pharmacol. 2011;72(3):490-9  
Willemsen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG.  
Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.  
Diabetes Care. 2011;34(2):369-74  
H.J.M.J. Crijns, S.M. Straus, C.h. Gispen-de Wied, L.T.W De Jong-van den Berg : Compliance with Pregnancy Prevention Programs of isotretinoin in Europe: a systematic review  
British Journal of Dermatology 2011;164(2):238-44  
Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA, Straus S, Stricker BH, Visser LE.  
Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.  
Br J Haematol. 2011 May;153(3):379-85

van Noord C, Sturkenboom MC, Straus SM, Witteman JC, Stricker BH.  
Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death.  
Heart. 2011;97(3):215-20  
Thijs J, Giezen Aukje K, Mantel-Teeuwisse, Ronald H.B, Meyboom, Sabine M.J.M. Straus, Hubert G.M. Leufkens, and Toine C.G. Egberts  
Mapping the Safety Profile of Biologicals.  
A Disproportionality Analysis Using the WHO Adverse Drug Reaction Database, VigiBase  
Drug Saf;2010;3:865-878

Peter G.M. Mol, Sabine M.J.M. Straus, Sigrid Piening, Jonie T.N. de Vries, Pieter A. de Graeff and Flora M. Haaijer-Ruskamp  
A Decade of Safety-related Regulatory Action in the Netherlands. A Retrospective Analysis of Direct Healthcare Professional Communications issued by Pharmaceutical Companies in Collaboration with the Dutch Medicines Evaluation Board and European Medicines Agency (EMA) from 1999 to 2009.  
Drug Saf 2010;33:463-74  
Martina Teichert, Loes E Visser, Mark Dufour, Eline Rodenburg, Sabine MJM Straus, Peter AGM De Smet, Bruno HCh Stricker

Isotretinoine use and compliance with the Dutch pregnancy prevention program: a retrospective cohort study in Dutch females of reproductive age with pharmacy dispensing data.  
*Drug Saf*;2010; 33:315-26

van Noord C, Sturkenboom M, Straus S, Hofman A, Kors J, Witteman J, Stricker B  
 Serum glucose and insuline are associated with Qtcand RR intervals in non diabetic elderly.  
*Eur J Endocrinol* 2010;162:241-248

van Noord C, Dörr M, Sturkenboom MC, Straus SM, Reffelmann T, Felix SB, Hofman A, Kors JA, Haring R, de Jong FH, Nauck M, Uitterlinden AG, Wallaschofski H, Witteman JC, Völzke H, Stricker BH.  
 The association of serum testosterone levels and ventricular repolarization  
*Eur J Epidemiol.* 2010;25(1):21-8

Thijs J. Giezen, Aukje K. Mantel-Teeuwisse, Sabine M.J.M. Straus, Antoine C.G. Egberts, Stella Blackburn, Ingemar Persson, Hubert G.M. Leufkens.  
 Evaluation of Post-Authorisation Safety Studies in the first cohort of EU Risk Management Plans at time of regulatory approval: Where are we?"  
*Drug Saf* 2009; 32 (12): 1175-1187

Charlotte van Noord, MD, Miriam C.J.M. Sturkenboom, PharmD, PhD, Sabine M.J.M. Straus MD, PhD, Albert Hofman, MD, PhD, Jacqueline C.M. Witteman, PhD, Bruno H. Ch. Stricker, MMed, PhD  
 Population-based studies of antithyroid drugs and sudden cardiac death  
*Br J Clin Pharmacol* 2009;68 (3): 447454

Thijs J. Giezen, Sabine M.J.M. Straus, Aukje K. Mantel-Teeuwisse  
 Pharmacovigilance of biosimilars from a regulatory point of view: Is there a need for a specific approach?  
*International Journal of Risk & Safety in Medicine* 2009 (21) 5358

Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC, Sturkenboom MC.  
 Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs.  
*Pharmacoepidemiol Drug Saf.* 2009;18(7):631-8

Charlotte van Noord, Albert-Jan L.H.J. Aarnoudse, Mark Eijgelsheim,  
 Miriam C.J.M. Sturkenboom, Sabine M.J.M. Straus, Albert Hofman, Jan A. Kors, Christopher Newton-Cheh, Jacqueline C.M. Witteman, Bruno H.Ch. Stricker, Calcium channel blockers, NOS1AP and QTc prolongation. *Pharmacogenetics and Genomics*, 2009;19(4):260-6

van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton-Cheh C, Witteman JC, Stricker BH.  
 Psychotropic drugs associated with corrected QT interval prolongation.  
*J Clin Psychopharmacol.* 2009 ; 29(1):9-15

van Noord C, van der Deure WM, Sturkenboom MC, Straus SM, Hofman A, Visser TJ, Kors JA, Witteman JC, Stricker BH.  
 High free thyroxine levels are associated with QTc prolongation in males.  
*J Endocrinol.* 2008;198(1):253-60.

Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC  
 Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs.  
*Obesity* 2008;16(10):2331-5.

Giezen T, Mantel-Teeuwisse A, Straus S, Schellekens H, Leufkens H, Egberts A  
 Safety-related regulatory actions for biologicals approved in the US and Europe since 1995.  
*JAMA* 2008;300(16):1887-1896.

Giezen T, PharmD; Mantel-Teeuwisse A, PhD, Leufkens H, PhD, Egberts A, PhD, Straus S, MD

PhD.

Risk management of biopharmaceuticals: A regulatory perspective.

European Journal of Hospital Pharmacy Practice. 2007;6: 72 -74

van der Sande MA, van Asten L, Straus SM, Schim van der Loeff MF, Wallinga J, Conyn-vanSpaendonck MA

Sudden deaths following influenza vaccination: Can this be expected?

Vaccine 2008; 26(3):379-82.

Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A, Uitterlinden AG, Witteman JC, Stricker BH

Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study.

Circulation. 2007;116(1):10-6

Sabine M.J.M. Straus, Jan A. Kors, Marie L. De Bruin, Cornelis S. van der Hooft, Albert Hofman, Jan Heeringa, Jaap W. Deckers, J Herre Kingma, Miriam CJM Sturkenboom, Bruno HCh Stricker, Jacqueline C.M. Witteman.

Prolonged QTc interval and risk of sudden cardiac death in a population of older adults.

J Am Coll Cardiol. 2006;47(2):362-7.

Dieleman JP, van Wyk JT, van Wijk MA, van Herpen G, Straus SM, Dunselman H, Sturkenboom MC.

Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin. 2005; 9:1461-8

Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH.

Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study.

Eur Heart J. 2004 (18):1614-9.

Straus SMJM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC.

Antipsychotics and the risk of sudden cardiac death.

Arch Intern Med. 2004;164(12):1293-7.

Straus SMJM, Bleumink GS, Dieleman JP, Lei van der J, Stricker BHCh, Sturkenboom MCJM.

Incidence of sudden cardiac death in the general population.

J Clin Epidemiol. 2004;57(1):98-102.

#### Nederlandse publicaties

C. van Noord, .S M.J.M. Straus, R van Mechelen, J.M. Akkerhuis, M. C.J.M. Sturkenboom, B. H. Ch. Stricker.

QTc-verlenging bij electrocardiografie en medicatie in de praktijk.

Modern Medicin 2009;33(6):193-6

Swaan CM, van der Sande MA, Speelman P, Conyn-van Spaendonck MA, Straus SM, Coutinho RA. Bijwerkingen van influenza vaccinatie [Adverse events following influenza vaccination: reaction to specific reports and the necessity of a central registration system]

Ned Tijdschr Geneeskd. 2007;151(39):2166-9..

Straus S.M.J.M, Lekkerkerker J.F.F.

Kennis zonder bijwerkingen

Medisch Contact 2004;37:144-1446

Voordouw ACG, Straus SMJM. Kunnen er weer griepachtige verschijnselen ontstaan na een 2e vaccinatie tegen hepatitis B? [What is known about the recurrence of flu-like symptoms following a second vaccination against hepatitis B?]

Vademecum, 2001, nr.22

van Grootheest AC, Straus SMJM, Heeringa M.

Bijwerkingen van Sildenafil, 2 jaar praktijkervaring [Side effects of sildenafil: findings from two years



practical experience]

Ned Tijdschr Geneesk. 2001 ;145(11):526-9.

Straus S, Nab HW, Meiners AP, Broekmans AW

Post-marketing surveillance: wetenschappelijk onderzoek of promotie van geneesmiddelen.

Huisarts en wetenschap 1999 ; 42: 505-08

SMJM Nierop-Straus

Acupunctuur en verslaving.

Acupunctur 1989;13:14-24

WMA Verhoeven en S. Straus

Neuropeptiden en depressie

Tijdschrift voor psychiatrie 1986 (9):622-32

#### Projects

involvement in supervision of academic research/PhD research , covering (additional) risk minimisation measures, medication errors, risk communication, methodology in signal detection, renal ADR and biologicals.

advisory role in

SAFEGUARD (The European project SAFEGUARD aims to assess and further quantify and understand the cardio/cerebrovascular and pancreatic safety of blood glucose lowering agents, in particular the thiazolidinedones (TZDs) and the novel incretin-based drugs and amylin analogues in Type 2 Diabetes Mellitus (T2DM) patients)

ARITMO (the European project ARITMO aims to analyse the arrhythmic potential of drugs in the following classes of study drugs (> 250 compounds): antipsychotics, anti-infectives (antibacterials, antimycotics and antivirals ) and H1-antihistamines, globally and in specific subgroups (age, co-morbidity, genetically).

#### Memberships

ISPE

#### Other Relevant Information